Meeting Coverage:

American Academy of Ophthalmology

AAO: 2020

Evaluation of Avacincaptad Pegol for the Treatment of GA Associated With AMD

Show Description +

Donald J. D'Amico, MD, presents the 18-month data of the phase 2/3 GATHER1 trial, which evaluated the monthly intravitreal injection of the novel C5 inhibitor avacincaptad pegol (Zimura, Iveric bio) for the treatment of geographic atrophy associated with AMD.

Posted: 11/05/2020

Up Next


Entrustable Physician Activities

Thomas A. Oetting, MD

Deep Learning: OCT and Disease Prediction

Tien Y. Wong, MD, MBBS, MPH, FRCS(Ed), Phd

Genetic Targeting & Glaucoma

Milica Margeta, MD

Does This New IOL Deliver?

Devesh K. Varma, MD

Evaluation of Avacincaptad Pegol for the Treatment of GA Associated With AMD

Donald J. D'Amico, MD, presents the 18-month data of the phase 2/3 GATHER1 trial, which evaluated the monthly intravitreal injection of the novel C5 inhibitor avacincaptad pegol (Zimura, Iveric bio) for the treatment of geographic atrophy associated with AMD.

Posted: 11/05/2020


Please log in to leave a comment.

More From AAO: 2020 Coverage